FDA
-
-
-
-
-
-
-
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
-
-
-
-
-
-
-
Aurinia to present LUPKYNIS data at medical conferences
-
-
-
-
-
-
-
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
-
-
-
-
-
-
-
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Announces Board Changes
-
-
-
-
-
-
-
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
-
-
-
-
-
-
-
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
-
328,575 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

